The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has released an updated version of the adult immunization schedule for ages 19 years and older in the United States. 

The immunization schedule has been approved by CDC, the American College of Physicians, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, the American College of Nurse-Midwives, the American Academy of Physician Associates, and the Society for Healthcare Epidemiology of America.


Continue Reading

Major changes to the adults immunization schedule for 2022 include the following:

Hepatitis B Vaccination

  • Routine Hepatitis B vaccination recommended in adults aged 19 to 59 years.
  • Hepatitis B vaccination is recommended for adults aged 60 years or older if they have an additional risk factor or another indication.
  • Anyone age 60 years or older who does not meet risk-based recommendations may still receive Hepatitis B vaccination.

Influenza Vaccination

  • Updated to reflect the recommendations for the 2021-2022 influenza season.

Meningococcal Vaccination

  • Meningococcal B vaccines may be administered simultaneously with Meningococcal ACWY vaccines if indicated, but at a different anatomic site, when feasible.

Pneumococcal Vaccination

  • For individuals 65 years or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown: 1 dose of PCV15 (15-valent pneumococcal vaccine; Vaxneuvance) or 1 dose of PCV20 (Prevnar 20).
  • For individuals 19-64 years old with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown: 1 dose of PCV15 or 1 dose of PCV20.
  • If PCV15 is administered, it should be followed by a dose of PPSV23 (pneumococcal 23-valent polysaccharide vaccine; Pneumovax 23) at least 1 year later.
  • Guidance for dosing intervals between PCV15 and PPSV23 and for patients who have previously received PCV13 or PPSV23 in the past is also included.

Zoster (Recombinant Zoster Vaccine [RZV]) Vaccination

  • Routine vaccination with RZV (Shingrix) recommended in persons aged 19 years or older who are or will be immunodeficient or immunosuppressed because of disease or therapy.
  • There is no ACIP recommendation for RZV use in pregnancy; consider delaying RZV until after pregnancy.

For additional guidance on the use of each vaccine appearing in the schedule, including precautions and contraindications, clinicians can view the respective ACIP vaccine recommendations at cdc.gov.

Interim clinical considerations for the use of COVID-19 vaccines can be found here.

Reference

US Centers for Disease Control and Prevention. Murthy N, Wodi AP, Bernstein H, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule For Adults Aged 19 Years Or Older — United States, 2022. MMWR Morb Mortal Wkly Rep 2022;71:229–233. Accessed February 18, 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7107a1.htm.

This article originally appeared on MPR